A clinical trial to study the affect of allopurinol compared with placebo in patients of CKD
Phase 3
- Conditions
- Health Condition 1: N189- Chronic kidney disease, unspecifiedHealth Condition 2: N189- Chronic kidney disease, unspecified
- Registration Number
- CTRI/2021/04/033018
- Lead Sponsor
- DrDipankar Sircar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Age 18-75 years
2.eGFR by CKD-EPI 10-45 ml/min/1.73m2
3.Serum uric acid >_6mg/dl
4.Clinically stable for last 3 months as judged by treating physician
Exclusion Criteria
1.Receiving Long term hemodialysis
2.Receiving immunosuppression therapy
3.Diagnosis of Gout
4.Diagnosis of CLD
5.Diagnosis of malignancy
6.Having received hypouricemic therapy in last 30 days
7.History of allergy to allopurinol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite of MACE(major adverse cardiovascular outcomes),CAD,PVD,CVA,any coronary or peripheral revascularization procedure and death due to CVD.Timepoint: outcomes would be assessed at 3,6,9 and 12 months
- Secondary Outcome Measures
Name Time Method eed for RRT,composite of 50% decline in GFR and need for RRT,change in eGFRTimepoint: 6 and 12 months